Effects of Subanesthetic Oromucosal Dexmedetomidine on Sleep in Humans: A Randomized, Controlled Pharmacokinetics–Pharmacodynamics Study
The favorable pharmacokinetic and pharmacodynamic profile of oromucosal dexmedetomidine delivery warrants further dose-finding and clinical studies to establish the exact roles of α 2 receptor agonism in pharmacologic sleep enhancement and as a possible novel mechanism to alleviate stress-related insomnia.
Authors
- Oliver G. Bosch (ORCID: https://orcid.org/0000-0002-5807-0859)
- Rafael Wespi (ORCID: https://orcid.org/0000-0002-3416-3938)
- Corinne Eicher (ORCID: https://orcid.org/0000-0003-4089-2456)
- Jonas Kost (ORCID: https://orcid.org/0009-0004-8331-5282)
- Hans‐Peter Landolt (ORCID: https://orcid.org/0000-0003-0887-9403)
- Martina I. Boxler (ORCID: https://orcid.org/0000-0002-9477-0158)
- Laura K. Schnider (ORCID: https://orcid.org/0009-0005-6332-5712)
- Dario Dornbierer (ORCID: https://orcid.org/0000-0001-9946-2069)
- Clarissa D. Voegel (ORCID: https://orcid.org/0000-0002-5480-7956)
- Eus J.W. Van Someren (ORCID: https://orcid.org/0000-0002-9970-8791)
- Laurenz Marten
- Jacqueline G. Kientsch
- Francesco Bavato
- Maxim Puchkov
- Marta Ratajczak
Institutions
- Netherlands Institute for Neuroscience (NL)
- University of Basel (CH)
- ZHAW Zurich University of Applied Sciences (CH)
- University of Zurich (CH)
- University Hospital of Zurich (CH)
Publication Details
- Journal
- Anesthesiology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1097/aln.0000000000005314
- Citations
- 7
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 2.40
Funders
- Wellcome Trust
- Innosuisse - Schweizerische Agentur für Innovationsförderung